Department Of General Services Virginia

The Department of General Services Virginia, Division of Consolidated Laboratory Services, is a state government entity that provides laboratory testing and scientific services to federal agencies as a prime contractor (89% of recent awards) under full-and-open competition with no SBA set-asides. DCLS operates as Virginia's public health laboratory from Richmond, Virginia, delivering specialized capabilities in microbiology, chemistry, radiochemistry, and genomics testing across defense health, public health surveillance, environmental monitoring, and biological threat detection missions.

DCLS holds a concentrated portfolio of newborn screening and infectious disease testing contracts anchored to the Defense Health Agency and the Department of the Navy. The Defense Health Agency drives the largest dollar concentration, with nine awards totaling $11.4 million in combined potential value—primarily delivery orders for newborn metabolic screening services at Naval Medical Center Portsmouth and Fort Belvoir military medical facilities, including a single-award Indefinite Delivery Contract (N6264521D5006, six task orders, $2.2 million combined potential value) and another IDC (N6264516D5013, six task orders, $1.8 million) running through 2031. The Department of the Navy Bureau of Medicine and Surgery placed 23 awards totaling $4.1 million, substantially overlapping with Defense Health Agency work through Naval Medical Center Portsmouth newborn screening delivery orders under IDC N0018906D0065 (13 task orders, $477 thousand combined potential value). The Department of State Bureau of Administration, the Department of Homeland Security Countering Weapons of Mass Destruction office, and the U.S. Geological Survey round out the customer base; State places recurring environmental sample testing contracts ($35 thousand to $38.4 thousand annually), while DHS CWMD funds BioWatch laboratory technical and management support ($26.7 thousand to $100 thousand per year).

DCLS holds ISO/IEC 17025 accreditation for seven chemical methods and five microbiological methods and competes across testing laboratory and medical laboratory NAICS categories (42 and 37 awards respectively) with firm fixed-price purchase orders and delivery orders representing the dominant contract types. Recent prime contract examples include a $1.656 million purchase order (May 1, 2026, Defense Health Agency, ultimate completion April 30, 2031) for newborn screening services extending beyond a parent $6.072 million IDC ceiling, a $100 thousand purchase order (September 27, 2026, Federal Emergency Management Agency via Countering Weapons of Mass Destruction, ultimate completion September 26, 2027) for BioWatch laboratory technical and management support, a $1.38 million purchase order (November 6, 2023, Defense Health Agency, ultimate completion November 5, 2028) for newborn metabolic screening at A.T. Augusta Military Medical Center, and a $24.675 thousand purchase order (September 11, 2024, U.S. Geological Survey, ultimate completion August 31, 2027) for water and sediment sample analysis supporting the Chesapeake Bay Non-tidal Network.

DCLS acts as prime recipient on federal grants anchoring its expansion and modernization pipeline. A $3.477 million FDA Cooperative Agreement (CFDA 93.103, awarded September 20, 2025, ultimate completion June 30, 2030) supports maintenance and expansion of ISO/IEC 17025 accreditation to include up to three new food testing methods and delivers emergency testing, surveillance, and regulatory human and animal food testing for FDA and the Food Emergency Response Network. DCLS also holds a CDC Cooperative Agreement as the lead Virginia Pathogen Genomics Center of Excellence (awarded September 30, 2022, ultimate completion September 29, 2027), collaborating with Virginia Department of Health, Virginia Commonwealth University, and University of Virginia on pathogen genomics translation, variant surveillance, and infectious threat response. Additionally, DCLS receives sub-awards from the Commonwealth of Virginia State Board of Health and the Virginia Department of Health funding disease surveillance and outbreak investigation support, wastewater monitoring, harmful algal bloom cyanotoxin detection, data modernization, and next-generation sequencing capacity expansion for COVID-19 and emerging infectious diseases.

Activity has grown irregularly—five awards in 2022, six in 2023, six in 2024, thirteen in 2025, and six in 2026 to date—with only four awards (combined potential value $160 thousand) reaching ultimate completion inside the next twenty-four months and therefore exposed to recompete risk. The combined dollars obligated across all awards ($118.3 million) substantially exceed the combined potential value ($24.7 million), indicating the source data captures both active long-running IDCs and completed awards over a multi-decade window since 1991.